UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
science & technology (193) 193
life sciences & biomedicine (188) 188
humans (185) 185
oncology (164) 164
female (160) 160
middle aged (128) 128
aged (118) 118
adult (105) 105
breast cancer (102) 102
life sciences (79) 79
breast neoplasms - drug therapy (75) 75
cancer (61) 61
male (55) 55
antineoplastic combined chemotherapy protocols - therapeutic use (53) 53
immunology (53) 53
chemotherapy (51) 51
breast neoplasms - pathology (48) 48
mesh: humans (46) 46
treatment outcome (45) 45
aged, 80 and over (44) 44
[sdv.imm]life sciences [q-bio]/immunology (43) 43
mesh: female (38) 38
neoplasm metastasis (33) 33
trastuzumab (33) 33
mesh : humans (32) 32
[ sdv.imm ] life sciences [q-bio]/immunology (31) 31
disease-free survival (31) 31
breast neoplasms (30) 30
france (29) 29
care and treatment (28) 28
metastasis (28) 28
mesh: aged (27) 27
mesh: middle aged (27) 27
hematology, oncology and palliative medicine (26) 26
antineoplastic combined chemotherapy protocols - adverse effects (25) 25
mesh : female (25) 25
metastatic breast cancer (25) 25
analysis (24) 24
antineoplastic agents - therapeutic use (24) 24
prognosis (24) 24
mesh: breast neoplasms (23) 23
drug administration schedule (22) 22
breast neoplasms - mortality (21) 21
antineoplastic agents (20) 20
pharmacology & pharmacy (20) 20
retrospective studies (20) 20
survival analysis (20) 20
antibodies, monoclonal, humanized - administration & dosage (19) 19
antineoplastic combined chemotherapy protocols (19) 19
bevacizumab (19) 19
medicine & public health (19) 19
mesh: adult (19) 19
research (19) 19
taxoids - administration & dosage (19) 19
antineoplastic agents - adverse effects (18) 18
neoplasm staging (18) 18
receptor, erbb-2 - metabolism (18) 18
breast neoplasms - genetics (17) 17
clinical trials (17) 17
mesh : breast neoplasms (17) 17
prospective studies (17) 17
survival (17) 17
[sdv.can]life sciences [q-bio]/cancer (16) 16
antineoplastic agents - administration & dosage (16) 16
france - epidemiology (16) 16
kaplan-meier estimate (16) 16
mesh : middle aged (16) 16
mesh: antineoplastic combined chemotherapy protocols (16) 16
skin and connective tissue diseases (16) 16
cancer therapies (15) 15
chemotherapy, adjuvant (15) 15
epidermal growth factor (15) 15
erbb-2 protein (15) 15
mesh : aged (15) 15
obstetrics & gynecology (15) 15
patients (15) 15
breast neoplasms - diagnosis (14) 14
breast neoplasms - metabolism (14) 14
capecitabine (13) 13
deoxycytidine - analogs & derivatives (13) 13
mesh: treatment outcome (13) 13
risk factors (13) 13
time factors (13) 13
tumors (13) 13
young adult (13) 13
antimitotic agents (12) 12
colorectal cancer (12) 12
mammography (12) 12
mesh : antineoplastic combined chemotherapy protocols (12) 12
mesh: france (12) 12
mesh: male (12) 12
neoplasm recurrence, local - drug therapy (12) 12
neoplasms (12) 12
quality of life (12) 12
receptor, erbb-2 - genetics (12) 12
risk assessment (12) 12
animals (11) 11
antineoplastic agents - pharmacokinetics (11) 11
fluorouracil - administration & dosage (11) 11
health aspects (11) 11
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Drugs (New York, N.Y.), ISSN 0012-6667, 2007, Volume 67, Issue 12, pp. 1800 - 1801
... phase III Cancer trials designed to further evaluate the use of A Viewpoint by Xavier Pivot bevacizumab in metastatic breast cancer. These inMedical Oncology... 
Antibodies, Monoclonal, Humanized | Humans | Angiogenesis Inhibitors - therapeutic use | Antibodies, Monoclonal - therapeutic use | Vascular Endothelial Growth Factor A - antagonists & inhibitors | Breast Neoplasms - drug therapy | Bevacizumab
Journal Article
Journal Article
Journal of clinical oncology, ISSN 1527-7755, 11/2009, Volume 27, Issue 33, pp. 5538 - 5546
Purpose Cross-talk between human epidermal growth factor receptors and hormone receptor pathways may cause endocrine resistance in breast cancer. This trial... 
Life Sciences & Biomedicine | Oncology | Science & Technology | Triazoles - administration & dosage | Triazoles - adverse effects | Postmenopause - drug effects | Receptors, Estrogen - metabolism | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prognosis | Receptor, ErbB-2 - genetics | Humans | Middle Aged | Receptor, ErbB-2 - metabolism | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Carcinoma - mortality | Receptors, Progesterone - genetics | Breast Neoplasms - metabolism | Receptors, Progesterone - metabolism | Dose-Response Relationship, Drug | Nitriles - administration & dosage | Antineoplastic Agents, Hormonal - adverse effects | Neoplasm Invasiveness - pathology | Aged, 80 and over | Adult | Female | Quinazolines - administration & dosage | Carcinoma - pathology | Carcinoma - secondary | Carcinoma - drug therapy | Receptors, Estrogen - genetics | Double-Blind Method | Drug Administration Schedule | Risk Assessment | Biomarkers, Tumor - analysis | Antineoplastic Agents, Hormonal - administration & dosage | Kaplan-Meier Estimate | Proportional Hazards Models | Treatment Outcome | Breast Neoplasms - drug therapy | Disease-Free Survival | Maximum Tolerated Dose | Breast Neoplasms - pathology | Quinazolines - adverse effects | Survival Analysis | Breast Neoplasms - mortality | Aged | Biomarkers, Tumor - genetics | Carcinoma - metabolism | Neoplasm Staging | Nitriles - adverse effects | Index Medicus | Carcinoma | Quinazolines | Breast Neoplasms | Life Sciences | Immunology | Triazoles | Postmenopause | Nitriles | Antineoplastic Agents, Hormonal | Tumor Markers, Biological | Receptors, Estrogen | Neoplasm Invasiveness | Antineoplastic Combined Chemotherapy Protocols | Receptor, erbB-2 | Receptors, Progesterone | Kaplan-Meiers Estimate
Journal Article
Journal Article
Journal Article
Journal of clinical oncology, ISSN 1527-7755, 05/2013, Volume 31, Issue 14, pp. 1719 - 1725
Journal Article
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 05/2012, Volume 30, Issue 14, pp. 1594 - 1600
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 02/2010, Volume 28, Issue 6, pp. 976 - 983
Purpose To evaluate trastuzumab (H) and docetaxel (T) with or without capecitabine (X) as first-line combination therapy for human epidermal growth factor... 
Life Sciences & Biomedicine | Oncology | Science & Technology | Prognosis | Receptor, ErbB-2 - genetics | Capecitabine | Humans | Middle Aged | Receptor, ErbB-2 - metabolism | Bone Neoplasms - secondary | Soft Tissue Neoplasms - drug therapy | Bone Neoplasms - metabolism | Breast Neoplasms - metabolism | Feasibility Studies | Young Adult | Antibodies, Monoclonal, Humanized | Fluorouracil - administration & dosage | Aged, 80 and over | Adult | Female | Bone Neoplasms - drug therapy | Liver Neoplasms - secondary | Fluorouracil - analogs & derivatives | Soft Tissue Neoplasms - secondary | Deoxycytidine - administration & dosage | Liver Neoplasms - drug therapy | Soft Tissue Neoplasms - metabolism | In Situ Hybridization, Fluorescence | Survival Rate | Treatment Outcome | Breast Neoplasms - drug therapy | Taxoids - administration & dosage | International Agencies | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Liver Neoplasms - metabolism | Aged | Neoplasm Staging | Deoxycytidine - analogs & derivatives | Trastuzumab | Index Medicus | Liver Neoplasms | Breast Neoplasms | Life Sciences | Immunology | Taxoids | Fluorouracil | Antineoplastic Combined Chemotherapy Protocols | Antibodies, Monoclonal | Bone Neoplasms | Receptor, erbB-2 | Deoxycytidine | Soft Tissue Neoplasms
Journal Article
Journal Article
The lancet oncology, ISSN 1470-2045, 09/2013, Volume 14, Issue 10, pp. 933 - 942
Journal Article
Breast cancer research and treatment, ISSN 0167-6806, 7/2010, Volume 122, Issue 2, pp. 409 - 418
... • Xavier B. Pivot • Fernando Hurtado de Mendoza • Binghe Xu • Linda T. Vahdat • Ronald A. Peck • Pralay Mukhopadhyay • Henri H. Roche ´ Received: 16 January 2010... 
Epothilone | Oncology | Metastatic breast cancer | Ixabepilone | Medicine & Public Health | Overall survival | Life Sciences & Biomedicine | Science & Technology | South America | Breast Neoplasms - secondary | Capecitabine | United States | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Drug Resistance, Neoplasm | Antimetabolites, Antineoplastic - administration & dosage | Taxoids - therapeutic use | Fluorouracil - administration & dosage | Time Factors | Tubulin Modulators - administration & dosage | Adult | Female | Fluorouracil - analogs & derivatives | Risk Assessment | Deoxycytidine - administration & dosage | Europe | Risk Factors | Kaplan-Meier Estimate | Proportional Hazards Models | Treatment Outcome | Breast Neoplasms - drug therapy | Disease-Free Survival | Antibiotics, Antineoplastic - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Asia | Epothilones - administration & dosage | Breast Neoplasms - mortality | Aged | Anthracyclines - therapeutic use | Deoxycytidine - analogs & derivatives | Complications and side effects | Medical research | Cancer patients | Care and treatment | Anthracyclines | Analysis | Patient outcomes | Clinical trials | Medicine, Experimental | Product development | Metastasis | Index Medicus | Life Sciences | Immunology
Journal Article